P-236 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
Titel:
P-236 Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
Auteur:
Lucchetti, J. Angotti, L. Cortellini, A. Basso, M. Polito, M. Zoratto, F. Di Giacomo, E. Calegari, M. Lo Prinzi, F. Gemma, D. Signorelli, C. Veroli, M. Anghelone, A. Muscio, L. Galbato Di Cocco, B. Trombetta, G. Guerriero, S. Schietroma, F. Vincenzi, B. Tonini, G.